Overview Dividends

(CNA) CNA Financial - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US1261171003

Commercial Property, Casualty, Professional Liability, Surety, Marine

Property & Casualty Insurance
Market Cap in USD: 12,757m

IPO / Inception: 1985-07-11
Return 12m vs S&P 500: -11.6%

EPS (Earnings per Share)

EPS CAGR: 12.33%
EPS Trend: 61.6%

Last SUE: 1.98
Qual. Beats: 2

Revenue

Rev. CAGR: 5.62%
Rev. Trend: 96.4%

Last SUE: 2.47
Qual. Beats: 3

Dividends

Dividend Yield	3.85%
Yield on Cost 5y	5.94%
Yield CAGR 5y	22.38%
Payout Consistency	81.1%
Payout Ratio	36.7%

Risk via 5d forecast
Volatility	19.1%
Value at Risk 5%th	31.6%
Relative Tail Risk	0.84%

Reward TTM
Sharpe Ratio	0.11
Alpha	-4.76
CAGR/Max DD	0.57

Character TTM
Hurst Exponent	0.468
Beta	0.421
Beta Downside	0.446

Drawdowns 3y
Max DD	17.51%
Mean DD	5.99%
Median DD	5.50%

Description: CNA CNA Financial October 31, 2025

CNA Financial Corp. (NYSE:CNA) is a Chicago-based insurance holding company that underwrites commercial property and casualty (P&C) products in the U.S. and abroad. Its operations are organized into four segments-Specialty, Commercial, International, and Life & Group-covering professional liability, directors-and-officers, cyber, workers’ compensation, commercial auto, surety bonds, and a range of property and machinery coverages. The firm also offers loss-sensitive programs and run-off long-term care policies, and it has been a subsidiary of Loews Corporation since its founding in 1853.

Key recent metrics: CNA reported a 2023 combined ratio of 94.5%, indicating underwriting profitability, and generated $1.1 billion of net income on $13.6 billion of written premium. Its return on equity (ROE) hovered around 12%, above the sector average of roughly 9%. The company’s exposure to commercial real-estate risk is a material driver, as declining office occupancy and higher financing costs have pressured underwriting results across the P&C industry. Additionally, Loews holds an estimated 30% ownership stake, providing CNA with a stable capital backstop but also linking its performance to Loews’ broader conglomerate dynamics.

If you want a deeper, data-driven view of CNA’s valuation and risk profile, the ValueRay platform offers granular financial models and scenario analyses worth exploring.

Piotroski VR‑10 (Strict, 0-10) 4.5

Net Income (997.0m TTM) > 0 and > 6% of Revenue (6% = 874.1m TTM)

FCFTA 0.04 (>2.0%) and ΔFCFTA 0.20pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue -14.19% (prev -16.19%; Δ 1.99pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.04 (>3.0%) and CFO 2.62b > Net Income 997.0m (YES >=105%, WARN >=100%)

Net Debt (2.99b) to EBITDA (1.46b) ratio: 2.04 <= 3.0 (WARN <= 3.5)

Current Ratio 0.57 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (272.3m) change vs 12m ago -0.15% (target <= -2.0% for YES)

Gross Margin 30.96% (prev 32.81%; Δ -1.86pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 21.25% (prev 20.53%; Δ 0.72pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 10.64 (EBITDA TTM 1.46b / Interest Expense TTM 131.0m) >= 6 (WARN >= 3)

Altman Z'' 0.56

(A) -0.03 = (Total Current Assets 2.73b - Total Current Liabilities 4.79b) / Total Assets 69.76b

(B) 0.14 = Retained Earnings (Balance) 9.74b / Total Assets 69.76b

(D) 0.16 = Book Value of Equity 9.21b / Total Liabilities 58.43b

Total Rating: 0.56 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 74.57

1. Piotroski 4.50pt

2. FCF Yield 20.66%

3. FCF Margin 17.35%

4. Debt/Equity 0.31

5. Debt/Ebitda 2.04

6. ROIC - WACC (= 1.82)%

7. RoE 9.32%

8. Rev. Trend 96.41%

9. EPS Trend 61.58%

What is the price of CNA shares?

As of December 23, 2025, the stock is trading at USD 47.83 with a total of 424,384 shares traded.
Over the past week, the price has changed by +1.14%, over one month by +2.90%, over three months by +5.02% and over the past year by +3.04%.

Is CNA a buy, sell or hold?

CNA Financial has received a consensus analysts rating of 2.00. Therefor, it is recommend to sell CNA.

Strong Buy: 0
Buy: 0
Hold: 0
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the CNA price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	45	-5.9%
Analysts Target Price	45	-5.9%
ValueRay Target Price	52.6	10%

CNA Fundamental Data Overview December 18, 2025

Market Cap USD = 12.76b (12.76b USD * 1.0 USD.USD)
P/E Trailing = 12.877
P/S = 0.859
P/B = 1.1267
P/EG = 4.21
Beta = 0.408
Revenue TTM = 14.57b USD
EBIT TTM = 1.39b USD
EBITDA TTM = 1.46b USD
Long Term Debt = 2.97b USD (from longTermDebt, last quarter)
Short Term Debt = 500.0m USD (from shortTermDebt, last quarter)
Debt = 3.47b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.99b USD (from netDebt column, last quarter)
Enterprise Value = 12.23b USD (12.76b + Debt 3.47b - CCE 3.99b)
Interest Coverage Ratio = 10.64 (Ebit TTM 1.39b / Interest Expense TTM 131.0m)
FCF Yield = 20.66% (FCF TTM 2.53b / Enterprise Value 12.23b)
FCF Margin = 17.35% (FCF TTM 2.53b / Revenue TTM 14.57b)
Net Margin = 6.84% (Net Income TTM 997.0m / Revenue TTM 14.57b)
Gross Margin = 30.96% ((Revenue TTM 14.57b - Cost of Revenue TTM 10.06b) / Revenue TTM)
Gross Margin QoQ = 32.92% (prev 29.76%)
Tobins Q-Ratio = 0.18 (Enterprise Value 12.23b / Total Assets 69.76b)
Interest Expense / Debt = 1.04% (Interest Expense 36.0m / Debt 3.47b)
Taxrate = 21.44% (110.0m / 513.0m)
NOPAT = 1.10b (EBIT 1.39b * (1 - 21.44%))
Current Ratio = 0.57 (Total Current Assets 2.73b / Total Current Liabilities 4.79b)
Debt / Equity = 0.31 (Debt 3.47b / totalStockholderEquity, last quarter 11.32b)
Debt / EBITDA = 2.04 (Net Debt 2.99b / EBITDA 1.46b)
Debt / FCF = 1.18 (Net Debt 2.99b / FCF TTM 2.53b)
Total Stockholder Equity = 10.69b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.43% (Net Income 997.0m / Total Assets 69.76b)
RoE = 9.32% (Net Income TTM 997.0m / Total Stockholder Equity 10.69b)
RoCE = 10.20% (EBIT 1.39b / Capital Employed (Equity 10.69b + L.T.Debt 2.97b))
RoIC = 7.94% (NOPAT 1.10b / Invested Capital 13.79b)
WACC = 6.12% (E(12.76b)/V(16.23b) * Re(7.56%) + D(3.47b)/V(16.23b) * Rd(1.04%) * (1-Tc(0.21)))
Discount Rate = 7.56% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 33.33 | Cagr: 0.02%
[DCF Debug] Terminal Value 79.12% ; FCFE base≈2.44b ; Y1≈2.59b ; Y5≈3.08b
Fair Price DCF = 199.4 (DCF Value 53.97b / Shares Outstanding 270.7m; 5y FCF grow 6.62% → 3.0% )
EPS Correlation: 61.58 | EPS CAGR: 12.33% | SUE: 1.98 | # QB: 2
Revenue Correlation: 96.41 | Revenue CAGR: 5.62% | SUE: 2.47 | # QB: 3
EPS next Quarter (2026-03-31): EPS=1.25 | Chg30d=+0.010 | Revisions Net=+1 | Analysts=1
EPS next Year (2026-12-31): EPS=4.80 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=-2.0% | Growth Revenue=+6.2%

Additional Sources for CNA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle